On Nov 21, major Wall Street analysts update their ratings for $Medtronic (MDT.US)$, with price targets ranging from $87 to $105.
Citi analyst Joanne Wuensch maintains with a hold rating, and maintains the target price at $92.
Barclays analyst Matt Miksic maintains with a buy rating, and maintains the target price at $105.
Wells Fargo analyst Larry Biegelsen maintains with a buy rating, and maintains the target price at $98.
TD Cowen analyst Josh Jennings maintains with a buy rating, and maintains the target price at $95.
Mizuho Securities analyst Anthony Petrone maintains with a buy rating.
Furthermore, according to the comprehensive report, the opinions of $Medtronic (MDT.US)$'s main analysts recently are as follows:
While maintaining a positive outlook on the FY25 high single digit EPS growth exit rate as an indicator for future potential, it is anticipated that into FY26, the company will face challenges from ongoing foreign exchange pressures, dilutive impacts from new product introductions and capital rollouts, along with a minor tax disadvantage, potentially restricting a sustained return to high single digit EPS growth.
Following a recent quarterly report, Medtronic's revenue surpassed expectations, driven by performance in its cardiovascular, neuro, and diabetes sectors. Additionally, the company has raised its fiscal year 2025 guidance to between 4.75%-5.0%. Looking further ahead to fiscal year 2026, analysts predict that earnings growth may exceed revenue growth.
Here are the latest investment ratings and price targets for $Medtronic (MDT.US)$ from 7 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美東時間11月21日，多家華爾街大行更新了$美敦力 (MDT.US)$的評級，目標價介於87美元至105美元。
花旗分析師Joanne Wuensch維持持有評級，維持目標價92美元。
巴克萊銀行分析師Matt Miksic維持買入評級，維持目標價105美元。
富國集團分析師Larry Biegelsen維持買入評級，維持目標價98美元。
TD Cowen分析師Josh Jennings維持買入評級，維持目標價95美元。
瑞穗證券分析師Anthony Petrone維持買入評級。
此外，綜合報道，$美敦力 (MDT.US)$近期主要分析師觀點如下：
儘管對FY25高個位數每股收益增長的前景持積極態度，作爲未來潛力的指標，但預計在FY26公司將面臨來自持續匯率期貨壓力、新產品推出和資本投放的稀釋性影響，以及輕微的稅收劣勢等挑戰，這可能會限制持續回歸高個位數每股收益增長。
在近期的季度報告後，美敦力的營業收入超出預期，這得益於其心血管、神經和糖尿病部門的表現。此外，公司已將2025財年的指導上調至4.75%-5.0%。展望2026財年，分析師預測收益增長可能超過營業收入增長。
以下爲今日7位分析師對$美敦力 (MDT.US)$的最新投資評級及目標價：
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
